Shares of Cara Therapeutics CARA were flat in after-market trading after the company reported Q1 results.
Quarterly Results
Earnings per share rose 24.19% year over year to ($0.47), which beat the estimate of ($0.59).
Revenue of $1,935,000 decreased by 76.09% from the same period last year, which missed the estimate of $2,360,000.
Looking Ahead
Earnings guidance hasn't been issued by the company for now.
Cara Therapeutics hasn't issued any revenue guidance for the time being.
Details Of The Call
Date: May 10, 2021
Time: 04:30 PM
ET Webcast URL: https://edge.media-server.com/mmc/p/cty3fnf5
Technicals
Company's 52-week high was at $29.65
Company's 52-week low was at $12.16
Price action over last quarter: down 32.53%
Company Profile
Cara Therapeutics Inc is an emerging biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
